Abstract 2934: Cucurbitacin D enhances the therapeutic efficacy of docetaxel via targeting cancer stem cells and miR-145

Volume: 78, Issue: 13_Supplement, Pages: 2934 - 2934
Published: Jul 1, 2018
Abstract
Background: Docetaxel (DTX) is an FDA approved drug for the treatment of advanced prostate cancer (PrCa). However, chemo-resistance and toxicity limits its use in clinic. Accumulating evidence suggests that activation of cancer stem cells (CSCs) is one of the mechanisms leading to developing chemo-resistance Therefore, identification of new pharmacophores that can target CSCs may improve the therapeutic efficacy of docetaxel for the treatment of...
Paper Details
Title
Abstract 2934: Cucurbitacin D enhances the therapeutic efficacy of docetaxel via targeting cancer stem cells and miR-145
Published Date
Jul 1, 2018
Volume
78
Issue
13_Supplement
Pages
2934 - 2934
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.